NASDAQ$RLMD
Relmada Therapeutics Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Relmada reported preliminary and unaudited financial results for Q3 2022 and provided a corporate update.
Relmada Therapeutics announced Q3 2022 financial results, with a focus on the ongoing evaluation of REL-1017 for major depressive disorder (MDD). Top-line results from the RELIANCE III trial were recently announced, and the company anticipates further results from RELIANCE I before the year's end. Enrollment continues for RELIANCE II, with top-line results expected in 2023.
- RELIANCE III top-line results are being further evaluated.
- Top-line results from RELIANCE I are expected before the end of the year.
- Enrollment continues in RELIANCE II, with top-line results anticipated in 2023.
- Relmada remains confident in REL-1017's potential for adjunctive treatment of MDD.
Headline financials
Revenue & EPS history
Relmada · Revenue · Quarterly
-$562K
Forward guidance
Relmada is focused on advancing REL-1017 in clinical development and expects top-line results from RELIANCE I before the end of the year and RELIANCE II in 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2022
-1.6%
Avg return
Earnings day
-1.4%
Avg return
5 days after
+3.2%
Avg return
30 days after
35%
15 / 43 earnings
Positive
+10.8%
Q4 2024
Best reaction
-29.0%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.0% | -12.5% | — | |
| Q1 2026 | +1.2% | -6.1% | -11.4% | |
| Q3 2025 | +1.8% | +7.7% | +4.6% | |
| Q2 2025 | -2.5% | -5.6% | +174.1% | |
| Q1 2025 | +6.6% | +33.4% | +53.6% | |
| Q4 2024 | +10.8% | -5.1% | +33.2% | |
| Q3 2024 | -3.5% | -2.9% | -86.5% | |
| Q2 2024 | -29.0% | -29.0% | -25.9% | |
| Q1 2024 | -0.5% | -7.6% | -22.8% | |
| Q4 2023 | -19.6% | -12.0% | -22.1% | |
| Q3 2023 | -2.0% | -7.5% | -16.1% | |
| Q2 2023 | +3.0% | +17.4% | +34.5% | |
| Q1 2023 | -9.2% | -10.7% | -19.0% | |
| Q4 2022 | -3.0% | +4.3% | +12.8% | |
| Q3 2022 | +10.4% | +2.3% | -53.5% | |
| Q2 2022 | -0.7% | -2.8% | +8.9% | |
| Q1 2022 | -12.4% | -18.5% | -20.1% | |
| Q4 2021 | +7.5% | +10.4% | +4.9% | |
| Q3 2021 | -8.2% | -12.0% | -24.4% | |
| Q2 2021 | +4.8% | +0.6% | +13.6% | |
| Q1 2021 | -4.1% | +0.0% | -10.9% | |
| Q4 2020 | -10.4% | -7.4% | +4.3% | |
| Q3 2020 | +0.0% | +8.3% | +0.9% | |
| Q2 2020 | -0.3% | +7.7% | +0.0% | |
| Q1 2020 | +9.6% | +8.5% | +12.6% | |
| Q4 2019 | -0.1% | -1.7% | +19.7% | |
| Q3 2019 | -3.0% | -5.1% | +29.9% | |
| Q2 2019 | -4.0% | -8.5% | +106.8% | |
| Q1 2019 | +0.0% | +1.7% | +13.9% | |
| Q3 2018 | +5.1% | +2.6% | -1.7% | |
| Q1 2018 | -5.0% | +5.3% | -13.3% | |
| Q2 2018 | +0.0% | -2.1% | -3.5% | |
| Q4 2017 | +4.7% | +4.7% | -11.0% | |
| Q3 2017 | -2.0% | -2.0% | -20.6% | |
| Q2 2017 | -8.6% | -4.8% | -32.9% | |
| Q1 2017 | +7.4% | +0.0% | -19.3% | |
| Q3 2016 | -17.8% | — | — | |
| Q2 2016 | +2.7% | — | — | |
| Q1 2016 | -1.1% | — | — | |
| Q3 2015 | -2.5% | — | — | |
| Q2 2014 | +4.2% | — | — | |
| Q3 2014 | -4.6% | — | — | |
| Q1 2015 | +5.9% | — | — | |
| Q4 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro